ABNOM
☆ AI Dermatology — Free Service
د آلمان څخه د 2022 سټیفټنګ وارینسټ پایلو کې ، د ماډلډرم سره د مصرف کونکي رضایت د تادیه شوي ټیلی میډیسن مشورې په پرتله یوازې یو څه ټیټ و.
د آلمان څخه د 2022 سټیفټنګ وارینسټ پایلو کې ، د ماډلډرم سره د مصرف کونکي رضایت د تادیه شوي ټیلی میډیسن مشورې په پرتله یوازې یو څه ټیټ و.
relevance score : -100.0%
ReferencesQ‑switched Nd:YAG لیزر په اغیزمنه توګه د اوټا او ورته شرایطو درملنې لپاره پیژندل شوی دی. موږ یوه څیړنه ترسره کړه ترڅو معلومه کړو چې د high‑fluence 1064 nm Q‑switched Nd:YAG لیزر په غیر معمولي سیمو کې د منګولیا ځایونو لپاره څومره مؤثر دی، پرته له دې چې پوستکي روښانه کړي. موږ 61 ناروغان (ټول 70 زخمونه) مطالعه کړل. نیمایي زخمونه د لیزر سره درملنه شول، پاته زخمونه د مقایسې لپاره بې درملنې پاتې شول. موږ پایلې د میلانین کچه اندازه کولو لپاره د پیمانه او د میکسامیټر (Mexameter) په وسیله وارزولې. ناروغان د درملنې ګروپ کې اوسطاً 14 میاشتې او د مشاهدې ګروپ کې 18 میاشتې تعقیب شول. د مطالعې په پای کې، د پیمانه نمرو او میلانین کچه کې د درملنې او غیر درملنې ګروپونو ترمنځ د پام وړ توپیرونه وموندل شول، چې د لیزر درملنې ګروپ غوره پایلې ښودلې. High‑fluence Q‑switched Nd:YAG لیزر، پرته له دې چې د پوستکي روښانه کولو لامل شي، د دې غیر معمولي منګولیا ځایونو د درملنې لپاره اغیزمن او خوندي ثابت شوی.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
موږ د ABNOM لپاره د ځانګړي لیزر درملنې کارولو اغیزمنتوب او خوندیتوب مطالعه کړې ده، او هغه فکتورونه پېژندلي چې ممکن د دې موثریت ته اغېزه وکړي. موږ ۱۱۰ ناروغان وڅېړل چې ABNOM لري او د دوه څخه تر نهه لیزر درملنې یې ترلاسه کړې. موږ وموندله چې درملنه د اوږدې مودې لپاره ښه کار کوي، خو په زړو ناروغانو کې نه. دا په هغو ناروغانو کې هم مؤثره ده چې روښانه پوستکي لري (ډول III) او کوچني اغیزمن شوي سیمې (له ۱۰ سانتيمتره څخه کم) لري. د ABNOM سره میلاسما درلودل درملنه لږ اغیزمنه کړه. د اغیزمنو سیمو رنګ یا شمېر داسې نه ښکاري چې توپیر وکړي. شاوخوا ۱۰٪ ناروغان د درملنې وروسته تور ځایونه ترلاسه کوي. په پیل کې ډیری درملنې ښه پایلې ورکړې. زوړ ناروغان چې تور پوستکي او تور داغونه لري، د درملنې وروسته د تور داغونو احتمال لري. د ABNOM او میلاسما ناروغانو لپاره، غوره ده چې ټیټ انرژي لیزر وکاروئ ترڅو د میلاسما خرابیدو مخه ونیسئ.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ درملنه
د سپینولو اجنټان په ندرت سره مؤثر دي. د میلاسما برعکس، ABNOM د لیزر درملنې سره ښه کیدی شي او پرته له تکرار څخه د لرې کیدو لپاره پریښودل کېږي. د ABNOM لپاره لیزر درملنه له ۱۰ څخه تر ۲۰ ځله ترسره کیدی شي.
#QS1064 laser